

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/898,586 07/03/2001 Valerie L. Gerlach 15966-638CIP 2872 (Cura-138CIP 30623 7590 09/30/2003 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY **EXAMINER** AND POPEO, P.C. LI, RUIXIANG ONE FINANCIAL CENTER BOSTON, MA 02111 ART UNIT PAPER NUMBER

DATE MAILED: 09/30/2003

1646

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action	Application No.	Applicant(s)
	09/898,586	GERLACH ET AL.
	Examiner	Art Unit
	Ruixiang Li	1646
The MAILING DATE of this communication appears on the cover sheet with the correspondence address		
THE REPLY FILED 26 August 2003 FAILS TO PLACE T Therefore, further action by the applicant is required to average final rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appeal Examination (RCE) in compliance with 37 CFR 1.114.	oid abandonment of this application of the control	tion. A proper reply to a places the application in
PERIOD FOR RE	PLY [check either a) or b)]	
 a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the context of the	Advisory Action, or (2) the date set forth ater than SIX MONTHS from the mailing FILED WITHIN TWO MONTHS OF THe date on which the petition under 37 CFF extension and the corresponding amounted shortened statutory period for reply to later than three months after the mail	g date of the final rejection. E FINAL REJECTION. See MPEP R 1.136(a) and the appropriate extension and the fee. The appropriate extension originally set in the final Office action; or
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFF	·	
2. The proposed amendment(s) will not be entered be	ecause:	
(a) X they raise new issues that would require further consideration and/or search (see NOTE below);		
√(b) they raise the issue of new matter (see Note below);		
(c) they are not deemed to place the application in issues for appeal; and/or	n better form for appeal by mater	rially reducing or simplifying the
(d) they present additional claims without canceling	ng a corresponding number of fi	nally rejected claims.
NOTE: See Continuation Sheet.		
3. Applicant's reply has overcome the following reject	ion(s):	
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	parate, timely filed amendment
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See		dered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY to	o issues which were newly
7. For purposes of Appeal, the proposed amendment (explanation of how the new or amended claims wo	•	
The status of the claim(s) is (or will be) as follows:		
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>19 and 80-83</u> .		
Claim(s) withdrawn from consideration:		
8. The proposed drawing correction filed on is	a) approved or b) disapp	roved by the Examiner.
9. Note the attached Information Disclosure Statemen	·— · · · · · · · · · · · · · · · · · ·	•
10. Other:		
· · · ·		

Continuation She t (PTOL-303)

Continuation of 2. NOTE: the amended claim 19 recites, in part,"wherein said probe binds to at least nucleotides 45-56 of SEQ ID NO: 23 or the complement thereof". The new limitation requires a new search and consideration. In addition, the new limitation raise the issue of new matter. There is no support for such a limitation.

Continuation of 5. does NOT place the application in condition for allowance because: the rejection of claims 19 and 80-83 under 35 U. S. C. §112, 1st Paragraph (New Matter) remains. The specification merely discloses SEQ ID NO: 3, which comprises the 5' untranslated region (nucleotides 1-54 of SEQ ID NO: 23). However, there is no support in the specification for a genus of nucleic acid molecules comprising a nucleic acid sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 24 and further comprising the nucleotides of the 5' untranslated region of SEQ ID NO: 23 or a variant thereof.

If the amendment were entered, the rejection of claims 19 and 80-83 under 35 U.S.C. §112, second paragraph, and under 35 U.S.C. § 102 (e) as being anticipated by Au-Young et al. (WO200107612A2, 102 (e) date: July 21, 1999), would be overcome.

SUPERVISORY PATENT EXAMINER